Cytokine-induced killer cells
Trials 23
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00185757 | Jun 2004 → Dec 2012 | disease related to hematopoietic stem cell transplant, plasma cell myeloma | Stanford University | Completed | No outcome recorded |
| Phase 1/25 trials | ||||||
| Phase 1/2 | NCT05108077 | Mar 2022 → Dec 2023 | kidney cancer, urinary bladder cancer | Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus | Unknown | No outcome recorded |
| Phase 1/2 | NCT03757858 | Mar 2018 → Dec 2022 | digestive system cancer, metastatic malignant neoplasm, peritoneal neoplasm | Capital Medical University | Completed | No outcome recorded |
| Phase 1/2 | NCT03047525 | Feb 2017 → Jan 2019 | colorectal cancer, lung cancer, nasopharyngeal carcinoma, renal cell carcinoma | Xiaoyi Huang | Unknown | No outcome recorded |
| Phase 1/2 | NCT01898793 | Aug 2014 → Dec 2021 | acute myeloid leukemia | Washington University School of Medicine | Terminated | No outcome recorded Stop: Business |
| Phase 1/2 | NCT01868490 | Apr 2009 → Jan 2028 expected | cholangiocarcinoma, neuroblastoma | Siriraj Hospital | Enrolling by invitation | No outcome recorded |
| Phase 212 trials | ||||||
| Phase 2 | NCT03002831 | Nov 2016 → Oct 2019 | cancer of unknown primary site | Henan Cancer Hospital | Terminated | No outcome recorded |
| Phase 2 | NCT02489890 | Feb 2016 → Jul 2025 overdue | urinary bladder neoplasm | The First People's Hospital of Changzhou | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02490735 | Aug 2015 → Aug 2040 expected | esophageal squamous cell carcinoma | The First People's Hospital of Changzhou | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT02498756 | Aug 2015 → Aug 2038 expected | melanoma | The First People's Hospital of Changzhou | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT02487693 | Jul 2015 → Jun 2038 expected | ovarian carcinoma | The First People's Hospital of Changzhou | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02487992 | Jul 2015 → Jul 2043 expected | colorectal cancer | The First People's Hospital of Changzhou | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02490748 | Jul 2015 → Jun 2038 expected | cervical cancer | The First People's Hospital of Changzhou | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02493582 | Jul 2015 → Jul 2030 expected | lung adenocarcinoma | The First People's Hospital of Changzhou | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02485015 | Jun 2015 → Jun 2030 expected | gastric cancer | The First People's Hospital of Changzhou | Active not recruiting | No outcome recorded |
| Phase 2 | NCT01929499 | Sep 2013 → Aug 2016 | colonic neoplasm | Yanjuan Zhu | Unknown | No outcome recorded |
| Phase 2 | NCT01871480 | May 2013 → Nov 2015 | non-small cell lung carcinoma | Kunming Medical University | Terminated | No outcome recorded |
| Phase 2 | NCT01533727 | Aug 2011 → Dec 2017 | non-small cell lung carcinoma | Sun Yat-sen University | Withdrawn | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT02482454 | Jul 2012 → Jul 2030 expected | cholangiocarcinoma | The First People's Hospital of Changzhou | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT02419677 | Jan 2010 → Dec 2014 | colorectal cancer | The First People's Hospital of Changzhou | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT01749865 | Oct 2008 → Sep 2014 | hepatocellular carcinoma | Sun Yat-sen University | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT03084809 | May 2012 → Sep 2014 | colorectal cancer | China Meitan General Hospital | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT05676190 | Jan 2023 → Dec 2026 expected | colorectal cancer | ShiCang Yu | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 24 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | cytokine induced killer cells | “Cytokine induced killer cells ( CIK) characterized as fast amplification, strong anti-cancer activity and broad anti-tumor spectrum” NCT01533727 ↗24“Immunotherapy with cytokine-induced killer cells (CIK) may improve tumor control and survival, as well as a better quality of life.” NCT01871480 ↗ “cultured cytokine-induced killer cells for 15-20 days. Cells were infused back to the patients” NCT03757858 ↗ “Treatment of Colorectal Cancer With Autologous Cytokine Induced Killer Cells (CIK)” NCT05676190 ↗ “Treatment of Colorectal Cancer With Autologous Cytokine Induced Killer Cells (CIK)” NCT05676190 ↗ “cytokine-induced killer cells (CIK) therapy” NCT01929499 ↗ |
| Known as | CIK | “Combinations of Dendritic and Cytokine-induced Killer Cells (DC-CIK) and Cytokine-induced Killer Cells (CIK) treatment may enhance the immune response and stop cancer cells...” NCT03047525 ↗8“CIK cells transfected with cytokine genes possess an improved proliferation rate and a higher cytotoxic activity as compared to regular CIK cells.” NCT02487992 ↗ “Cytokine induced killer cells ( CIK) characterized as fast amplification, strong anti-cancer activity and broad anti-tumor spectrum” NCT01533727 ↗ “Immunotherapy with cytokine-induced killer cells (CIK) may improve tumor control and survival, as well as a better quality of life.” NCT01871480 ↗ “Cytokine-induced killer (CIK) cells exhibit high proliferation rate and cytotoxic activity in vitro.” NCT01868490 ↗ “cytokine-induced killer (CIK) cells are an effective tool against various types of solid tumors” PMID 26842696 ↗ Feb 2016 “Treatment of Colorectal Cancer With Autologous Cytokine Induced Killer Cells (CIK)” NCT05676190 ↗ “chemotherapy plus 3 cycles of Cytokine-induced Killer Cells(CIK) treatment” NCT02489890 ↗ “cytokine-induced killer cells (CIK) therapy” NCT01929499 ↗ |
| Known as | CIK cells | “CIK cells: intravenous infusions; D14-16; one cycle every month,at least 6 cycles;” NCT01871480 ↗ |
| Modality | Cell therapy | “use of activated T-cells to treat relapsed malignancy (cancer)” NCT00185757 ↗ |
| Route | Intravenous | “at least 10\*9 CIK cells, IV on day 0, 14, 28” NCT01868490 ↗ |